Richmond Brothers, Inc. Ocuphire Pharma, Inc. Transaction History

Richmond Brothers, Inc.

$161 Million
Q3 2024

A detailed history of Richmond Brothers, Inc. transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Richmond Brothers, Inc. holds 155,620 shares of OCUP stock, worth $152,507. This represents 0.13% of its overall portfolio holdings.

Number of Shares

155,620

Previous 191,304 18.65%

Holding current value

$152,507

Previous $292,000 30.48%

% of portfolio

0.13%

Previous 0.6%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$1.19 - $2.07 $42,463 - $73,865	-35,684 Reduced 18.65%	155,620 $203,000
Q2 2024 Aug 12, 2024	SELL	$1.51 - $2.23 $54,597 - $80,630	-36,157 Reduced 15.9%	191,304 $292,000
Q1 2024 May 09, 2024	SELL	$1.89 - $3.27 $47,832 - $82,757	-25,308 Reduced 10.01%	227,461 $457,000
Q4 2023 Feb 08, 2024	SELL	$2.59 - $3.64 $298,456 - $419,451	-115,234 Reduced 31.31%	252,769 $760,000
Q3 2023 Nov 02, 2023	BUY	$3.35 - $4.33 $87,579 - $113,199	26,143 Added 7.65%	368,003 $1.23 Million
Q2 2023 Aug 11, 2023	BUY	$3.63 - $6.38 $4,842 - $8,510	1,334 Added 0.39%	341,860 $1.48 Million
Q1 2023 May 10, 2023	BUY	$3.01 - $3.85 $34,783 - $44,490	11,556 Added 3.51%	340,526 $1.28 Million
Q4 2022 Feb 07, 2023	BUY	$2.04 - $3.53 $17,621 - $30,492	8,638 Added 2.7%	328,970 $1.16 Million
Q3 2022 Nov 01, 2022	BUY	$1.82 - $2.79 $16,765 - $25,701	9,212 Added 2.96%	320,332 $641,000
Q2 2022 Aug 12, 2022	BUY	$1.8 - $3.25 $335,836 - $606,372	186,576 Added 149.81%	311,120 $597,000
Q1 2022 May 05, 2022	BUY	$2.75 - $4.39 $137,841 - $220,044	50,124 Added 67.35%	124,544 $403,000
Q4 2021 Feb 10, 2022	BUY	$3.4 - $5.19 $253,028 - $386,239	74,420 New	74,420 $277,000

Others Institutions Holding OCUP

# of Institutions

Shares Held

2.58M

Call Options Held

14.1K

Put Options Held

800

View Full List

About Ocuphire Pharma, Inc.

Ticker OCUP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,579,800
Market Cap $20.2M
Description
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...

More about OCUP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Richmond Brothers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Richmond Brothers, Inc. with notifications on news.

Account

Richmond Brothers, Inc. Ocuphire Pharma, Inc. Transaction History